Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib in BRAF V600-mutant non-small cell lung cancer
NL-OMON54680Phase 2Recruiting
- Sponsor
- Array BioPharma
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib and binimetinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Array BioPharma. Primary endpoint: Objective response rate. Started Feb 2020; status: recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54680.